Hunt, Kelly K.
Suman, Vera J.
Wingate, Hannah F.
Leitch, A. Marilyn
Unzeitig, Gary
Boughey, Judy C.
Meric-Bernstam, Funda
Ellis, Matthew J.
Olson, John A.
Article History
First Online: 6 February 2023
Disclosure
: Kelly K. Hunt: Consulting or advisory role for Armada Health, AstraZeneca, and Merck & Co.; research funding to MD Anderson Cancer Center from Cairn Surgical, Eli Lilly & Co, and Lumicell. Vera J. Suman: No relationships to disclose. Hannah F. Wingate: No relationships to disclose. A. Marilyn Leitch: Consulting or advisory role for Celgene, Genomic Health, and Castle Biosciences. Gary Unzeitig: No relationships to disclose. Funda Meric-Bernstam: Membership on Board of Directors or Advisory Committees (includes consulting) for Protai Bio Ltd, Astra Zeneca, Seagen (formerly Seattle Genetics), Zymeworks, OnCusp Therapeutics, Harbinger Health, Tallac Therapeutics, Daiichi Sankyo, Lengo Therapeutics, Sanofi Pharmaceuticals, FogPharma, Karyopharm, LOXO Oncology, Biovica, F. Hoffmann La-Roche. Judy C. Boughey: Consulting or advisory role for Cairn Surgical and SymBioSis; research funding to Mayo Clinic from Eli Lilly & Co. John A. Olson: Stock or other ownership in Core Prognostex. Matthew J. Ellis: Employment with AstraZeneca; patents, royalties, other intellectual property for PAM50-based diagnostics, including Prosigna (Veracyte).